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Summary  
Th2-promoting cytokine IL-33 has been implicated in asthma pathogenesis. 
Angiogenesis is a feature of airways remodelling in asthma. We hypothesised that 
IL-33 induces airways angiogenesis and expression of angiogenetic factors in an 
established murine surrogate of asthma. In the present study, BALB/c mice were 
subjected to serial intranasal challenge with IL-33 alone for up to 70 days. In parallel, 
OVA-sensitized mice were subjected to serial intranasal challenge with OVA or 
normal saline to serve as positive and negative controls, respectively.  
Immunohistochemical analysis of expression of Von Willebrand factor (vWF) and 
erythroblast transformation-specific (ETS) related gene (ERG), both blood vessel 
markers, and angiogenetic factors angiogenin, insulin-like growth factor (IGF-1), 
endothelin-1, epidermal growth factor (EGF) and amphiregulin was performed in lung 
sections ex vivo. An established in house assay was used to test whether IL-33 is able 
to induce microvessel formation by human vascular endothelial cells. Results showed 
that serial intranasal challenge of mice with IL-33 or OVA resulted in proliferation of 
peribronchial vWF+ blood vessels to a degree closely related to the total expression of 
the angiogenic factors amphiregulin, angiogenin, endothelin-1, EGF and IGF-1. IL-33 
also induced microvessel formation by human endothelial cells in a 
concentration-dependent fashion in vitro. Our data are consistent with the hypothesis 
that IL-33 has the capacity to induce angiogenesis at least partly by increasing local 
expression of multiple angiogenetic factors in an allergen-independent murine asthma 
surrogate, and consequently that IL-33 or its receptor are potential novel molecular 
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targets for asthma therapy.  
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Introduction  
Asthma is a chronic disease affecting more than 300 million people worldwide and its 
prevalence is still rising.
1
 It is characterised pathophysiologically by bronchial 
mucosal inflammation with Th2-type immune bias and episodic airways obstruction, 
reflecting airways hyperresponsiveness (AHR).
2
 Neo-angiogenesis in the airways 
mucosa is a distinct feature of asthma pathophysiology which is generally considered 
to be an important component of airways remodelling, which may contribute to 
irreversible airways obstruction. Neo-angiogenesis may be defined as the emergence 
of new blood vessels from pre-existing vasculature and is regulated by a balance of 
promoting (angiogenic) and counteracting (angiostatic) factors.
3,4
 In the course of 
chronic inflammation, neo-angiogenic processes are initiated as a result of the 
dominance of pro-angiogenic effects likely involving many growth factors.
5
 Given 
that neo- angiogenesis is a typical feature of remodelling in asthmatic airways, asthma 
is not only an airways disease, but also a vascular disease.
6
 Nevertheless there are 
relatively few reports addressing its pathogenesis in asthma. 
IL-33 is a member of the IL-1 cytokine family and is a ligand of the receptor 
ST2.
7
 Recent studies in human subjects and murine asthma surrogates suggest a 
central role for IL-33 in driving Th2-mediated inflammation.
8.9
 Direct administration 
of IL-33 alone into the airways of naive mice via the intranasal route resulted in 
elevated expression of Th2 cytokines, eosinophilic inflammation and AHR.
10-12
 
Deletion or blockade of the IL-33 receptor (T1/ST2) has been shown to attenuate 
allergic airways inflammation in animal asthma surrogates.
9,11
 Some studies suggest 
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that IL-33 also promotes angiogenesis and increases vascular permeability, possibly at 
least partly by promoting endothelial cellular production of nitric oxide and urokinase 
in human endothelial cells.
13,14
 
To examine the potential role of IL-33 to promote angiogenesis in asthma and 
clarify its mechanisms of action we utilized a murine surrogate of asthma initiated by 
direct IL-33 challenge which we developed as previously described
15
 to compare, in 
parallel, the effects of direct IL-33 challenge of the airways with those of “classical” 
ovalbumin (OVA) challenge necessitating prior IgE anti-OVA sensitisation of the 
animals as a positive control. In addition, using an in vitro model we investigate 
whether IL-33 exerts direct effects on human angiogenesis in vitro.  
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Materials and methods  
Animals 
Female BALB/c mice (8-10 weeks old) were obtained from Vital River Laboratories 
(Beijing, China) and maintained in a pathogen-free mouse facility located in the 
Department of Laboratory Animal Sciences, Capital Medical University, Beijing, 
China. All of the experimental procedures were approved by the Institutional Animal 
Care and Use Committee (IACUC). 
 
IL-33- and ovalbumin (OVA)-challenge  
The protocols employed for sensitization and inhalational challenge have 
previously been described.
15 
Mice were randomly distributed into 3 groups including 
a group serially challenged with 50μg/dose of OVA as a positive control;16,17 a group 
administered saline as a negative control and a group serially challenged with 
IL-33.
15,18
 The OVA-challenged mice were first sensitised by intraperitoneal injection 
of 100μg/dose OVA (Sigma-Aldrich, Beijing, China, emulsified in Al[OH]3) on days 
0 and 12. These mice were then further intranasally challenged daily on days 18 to 23 
with 50μg/dose of OVA (OVA50) in 50μL saline. For IL-33-challenge, naïve mice 
were challenged intranasally daily from days 18 to 23 with recombinant mouse IL-33 
(mIL-33, R&D Systems, 100 ng in 50μL saline = 1.1 x 10-7M).Then the mice in each 
group were further challenged intranasally with OVA or IL-33 every 2 days for a 
further 30 days. Some of them were observed for a further 17 days after cessation of 
the challenges. Control mice were intraperitoneally injected with same amount of 
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Al[OH]3 then nasally challenged with normal saline at corresponding time-points. 
Lung tissues were collected on days 20, 24, 36, 48, 54 and 70 (each time point n=5 for 
per group), respectively, 24 hrs after the most recent intranasal challenge e animals.
15
 
 
Lung immunohistochemistry 
Resected left lung tissue was fixed in 10% neutral-buffered formalin for 24 hr, then 
dissected and embedded in paraffin. Immunohistochemistry was used to detect major 
angiogenic biomarkers in 5-μm lung sections. Primary monoclonal antibodies 
against mouse erythroblast transformation-specific (ETS) related gene (ERG, 1:50), 
angiogenin (1:50), insulin-like growth factor(IGF-1, 1:400), endothelin-1 (1:600), and 
epidermal growth factor (EGF, 1:100) were purchased from Abcam (Hong Kong, 
China). Primary monoclonal antibody against mouse Von Willebrand factor (vWF, 
1:50) and amphiregulin (1:100) were purchased from Merck Millipore (Shanghai, 
China) and Santa Cruz Biotechnology, Inc (CA, USA) respectively. The PAP 
(peroxidase anti-peroxidase) technique was used for detection as previously 
described.
15,16
 Sections were anonymised by coding then independently analysed by 2 
observers using a Leica DM6000B microscope (Leica, Wetzlar, Germany) connected 
with a Leica Application Suite Version 3.6. Image-Pro Plus software was used to 
delineate and measure the total areas of each section showing positive staining in an 
objective fashion. For each biomarker three independent experiments were performed. 
The data were expressed as percentages of the entire areas of the lung sections 
showing positive staining.  
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In vitro angiogenesis assay 
We used a well established in vitro angiogenesis assay (AngioKit; TCS CellWorks, 
Buckingham, UK)
19,20
 which is based on co-culture of HUVEC over a monolayer of 
irradiated fibroblasts. Cultures were incubated at 37°C in a humidified atmosphere 
with 5% CO2. Culture medium with recombinant human IL-33 (0.1, 1.0 and 10 
ng/mL, R&D Systems, Abingdon, UK) was replenished on days 4, 7, and 9. On day 
11 cultured cells were fixed and vascular structures visualised by labelling with 
mouse anti-CD31 according to the manufacturer’s instructions. Culture medium alone 
and recombinant human VEGF-A (R&D Systems, 10 ng/mL) served as negative and 
positive assay controls. The analysis software (AngioSys; TCS CellWorks) segmented 
the images using a grey level threshold tool to select CD31-labelled cells. The overall 
numbers of vascular junctions, tubules, and tubule length were determined as 
described previously.
19,20
 
 
Statistical analysis 
All data are reported as the mean ± SEM and analysed using InStat 2.01 software 
(GraphPad, San Diego, CA, USA). Between-group comparisons at specific 
time-points were performed using 2-way parametric ANOVA followed by a 
Bonferroni post test or the Student’s unpaired t test. Data generated from the 
angiogenesis assay were analysed using Mann Whitney test. A p value <0.05 was 
considered significant.  
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Results 
IL-33 increased airways vascularity 
Compared with saline challenge, IL-33 induced marked airways angiogenesis as 
indicated by significantly elevated numbers of peribronchial, vWF
+ 
immunoreactive 
blood vessels, which appeared as early as day 20, peaked at day 48 and persisted until 
the end of the experiment (day70) (Figure 1). OVA challenge was associated with 
similar, statistically equivalent changes in vWF
+
 immunoreactive vessels.  
 ERG is constitutively expressed by endothelial cells and is considered as another 
biomarker of endothelial cell numbers and angiogenesis. Immunohistochemical 
analysis of ERG immunoreactivity similarly confirmed that, compared with saline 
challenge, both OVA- and IL-33-challenge induced significant expression of ERG, 
which was first apparent at day 36, peaked at day 48 and persisted until the end of the 
experiment (day 70) (Figure 2).  
 
IL-33 induced airways angiogenin and EGF expression 
Immunohistochemical analysis showed that compared with control, saline challenge, 
both OVA- and IL-33-challenge of airways significantly increased the expression of 
immunoreactivity for lung and parenchymal and peribronchial angiogenin and EGF. 
Elevated immunoreactivity for angiogenin and EGF was apparent from day 24, 
peaked at day 48 and persisted until day 70, the end of the experiments (Figures 3 and 
4).  
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IL-33 induced elevated airways IGF-1, endothelin-1 and amphiregulin 
expression 
Immunoanalysis showed that IL-33 as compared with saline challenge of the airways 
significantly increased expression of lung parenchymal and peribronchial IGF-1, 
endothelin-1 and amphiregulin immunoreactivity from day 20 (endothelin-1) or day 
24 (IGF-1 and amphiregulin) which persisted until the end of the experiment(Figures 
5, 6 and 7). OVA challenge again induced elevated expression of these growth factors 
with temporal courses statistically equivalent to those induced by IL-33 challenge. 
 
IL-33 induced human angiogenesis in vitro 
In an in vitro angiogenesis assay, IL-33 induced statistically significant increases in 
the numbers, lengthens and branching of microvessels produced by HUVEC in a 
concentration-dependent fashion (Figure 8). The effects of IL-33 at concentration of 
10 ng/mL were equivalent to those of VEGF at the same concentration, employed as a 
positive control. 
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DISCUSSION 
Angiogenesis, a feature of airways remodelling in asthma, can be defined as the 
emergence of new blood vessels from pre-existing vasculature. Although 
pathophysiological significance of this change still needs to be further explored, 
increased blood flow and permeability in asthmatic lung might contribute to oedema 
and local inflammation because neo-angiogenesis provides prerequisite for 
extravasation of inflammatory cells into local tissue. Some studies have shown that 
vascularity is associated with asthma severity.
1,3,4-6
 Previous investigations have also 
suggested that angiogenesis in asthmatics is closely related to the local expression of 
angiogenic factors.
 6,19, 21 
IL-33 and its ST2 receptor are expressed in the endothelial 
cells of human veins and arteries.
22
 In human endothelial cells, IL-33 induced 
inflammatory activation as evidenced by increased vascular permeability, increased 
production of inflammatory cytokines and the stimulation of angiogenesis.
13.23 
The 
data from the present study confirm that IL-33 has the capacity to induce angiogenesis 
in vivo and to increase local expression of multiple angiogenic growth factors in the 
epithelium and submucosal tissues of the airways in an established IL-33-induced 
allergen- independent murine surrogate of asthma. These changes were comparable to 
those induced by conventional OVA challenge of IgE-sensitised animals, a surrogate 
of allergic asthma, and significantly more marked with some analytes, particularly at 
the peak time point of expression at day 48. Furthermore, using an in vitro model of 
human angiogenesis, we have showed that IL-33 effects concentration-dependent 
microvessel formation, by endothelial cells in a manner comparable to that of VEGF, 
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a well established angiogenic agent. 
Angiogenesis is a complex process, likely regulated by a variety of both discrete 
and interacting local mechanisms. ERG, expressed throughout the life of the 
endothelium, appears to contribute to angiogenesis by regulating vascular homeostasis, 
vascular integrity and endothelial cell growth.
24, 25
 Inhibition of ERG in human 
umbilical vein endothelial cells causes loss of cell-cell contact and attenuation of 
microvessel formation.
26
 Angiogenin also appears to play a fundamental, if ill-defined 
role in vascular growth.
26,27
 Amphiregulin is a potent mitogen for several types of cell, 
including epithelial cells, vascular smooth muscle cells and endothelial cells acting 
via the epidermal growth factor receptor (EGFR).
28
 In addition, both innate and 
adaptive immune cells are able to express this molecule, suggesting that amphiregulin 
might play a role in orchestrating immunity, inflammation and tissue repair.
29
 
Interestingly, IL-33 can induce type 2 innate lymphoid cells to produce amphiregulin 
and Th2-type cytokines in vitro.
30
 Endothelin-1 is a potent vasoconstrictor which may 
also cause vascular remodelling, cellular proliferation, extracellular matrix production 
and capillary permeability.
31,32 
As a multifunctional vascular protein vWF has been 
implicated in the regulation of angiogenesis in many diseases from cancer to 
atherosclerosis.
33
 EGF promotes cellular proliferation and is involved in 
embryogenesis, angiogenesis and cellular differentiation.
34
 IGF-1 plays an important 
role in the physiology of endothelial cell structure and function by promoting 
migration, microvessel formation and production of VEGF and the vasodilator nitric 
oxide.
35
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Because angiogenesis is such a complex process, the question of how IL-33 
regulates angiogenesis directly or indirectly through effects on expression of these 
angiogenic factors in asthma and other diseases remain to be clarified. Recent studies 
indicate that IL-33 might contribute to the pathogenesis of angiogenesis-dependent 
and inflammatory vascular diseases by promoting production of endothelial NO and a 
range of additional mediators including IL-6, IL-8, monocyte chemoattractant 
protein-1 (MCP-1), vascular cell adhesionmolecule-1 (VCAM-1), intercellular 
adhesion molecule-1 (ICAM-1) and endothelial E-selectin.
13, 23,36
 IL-33 is 
constitutively expressed in the nuclei of vascular endothelial cells in various human 
tissues, with the apparent exception of tumor vessels.
37
 In line with these studies, we 
here show that IL-33 directly promotes angiogenesis in vitro, and in vivo in the setting 
of asthma-like inflammation of the airways, directly and/or indirectly by 
up-regulating a range of pro-angiogenic factors. Whatever the case, IL-33 may be a 
key molecular target for the inhibition of neo-angiogenesis and its consequences in 
the setting of asthma.  
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Figure legends 
Figure 1: IL-33 increased airways vWF immunoreactivity. 
A: Representative photomicrographs of vWF immunoreactive blood vessels in lung 
sections from saline (NS)-, OVA- and IL-33-challenged mice at various time points as 
indicated (light microscopy, ×200). B: Quantitative analysis of numbers of vWF
+ 
blood vessels per unit area of lung sections. Data are expressed as mean + SEM (n = 5 
mice in each group at each time-point). *P < 0.05. 
 
Figure 2: IL-33 increased airways ERG expression. 
A: Representative photomicrographs of ERG immunostaining in lung sections from 
saline (NS)-, OVA- and IL-33-challenged mice at various time points as indicated 
(light microscopy, ×400). B: Data are expressed as mean + SEM (n = 5 mice in each 
group at each time-point). *P < 0.05. 
 
Figure 3: IL-33 increased airways angiogenin expression. 
A: Representative photomicrographs of angiogenin immunoreactivity in lung sections 
from saline (NS)-, OVA- and IL-33-challenged mice at various time points as 
indicated (light microscopy, ×200). B: Data are expressed as mean + SEM (n = 5 
mice in each group at each time-point). *P < 0.05. 
 
Figure 4: IL-33 increased airways EGF expression. 
A: Representative photomicrographs of EGF immunoreactivity in lung sections from 
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saline (NS)-, OVA- and IL-33-challenged mice at various time points as indicated 
(light microscopy, ×200). B: Data are expressed as mean + SEM (n = 5 mice in each 
group at each time-point). *P < 0.05. 
 
Figure 5: IL-33 increased airways IGF-1 expression. 
A: Representative photomicrographs of IGF-1 immunoreactivity in lung sections 
from saline (NS)-, OVA- and IL-33-challenged mice at various time points as 
indicated (light microscopy, ×200). B: Data are expressed as mean + SEM (n = 5 
mice in each group at each time-point). *P < 0.05. 
 
Figure 6: IL-33 increased airways endothelin-1 expression. 
A: Representative photomicrographs of endothelin-1 immunoreactivity in lung 
sections from saline (NS)-, OVA- and IL-33-challenged mice at various time points as 
indicated (light microscopy, ×200). B: Data are expressed as mean + SEM (n = 5 
mice in each group at each time-point). *P < 0.05. 
 
Figure 7: IL-33 increased airways amphiregulin expression. 
A: Representative photomicrographs of amphiregulin immunoreactivity in lung 
sections from saline (NS)-, OVA- and IL-33-challenged mice at various time points as 
indicated (light microscopy, ×200). B: Data are expressed as mean + SEM (n = 5 
mice in each group at each time-point). *P < 0.05. 
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Figure 8: IL-33 induced angiogenesis in vitro.  
Top panel: representative light photomicrographs (4x original magnification) show 
formation of primitive vascular tubule structures by human vascular endothelial cells 
after 11 days of culture with medium control, VEGF (10 ng/mL) and IL-33 (0.1, 1.0 
and 10 ng/mL). Bottom panel: computer-assisted quantification of mean total 
numbers of tubules, mean total tubule lengths and mean numbers of branch points. 
Bars show the mean±SEM of three separate experiments performed in duplicate. *P 
< 0.05.  
 
